Michael Detke

Michael Detke, MD, PhD, serves as the Chief Medical Officer and Co-Founder of Lighthouse Pharma, focusing on clinical development strategies for small molecule therapeutics aimed at dementia and degenerative disorders since September 2022. Concurrently, Michael holds the position of Acting Chief Medical Officer at Neumarker, Inc., where responsibilities include integrating biomarkers into clinical strategies. Since 2013, Michael has been the President of Detke Biopharma Consulting LLC, offering expertise in CNS clinical development to various clients. Additionally, Michael is a Clinical Professor of Psychiatry at Indiana University School of Medicine, involving part-time patient care and teaching. Previous roles include Chief Medical Officer at Cortexyme, Inc., Embera NeuroTherapeutics, Inc., and MedAvante, as well as Executive Director at Eli Lilly and Company, directing CNS assets. Michael's educational background includes a residency in Psychiatry from Harvard Medical School, and an MA, MD, and PhD in Psychology from the University of Pennsylvania, along with a BA and MS in Psychology from Yale University.